Hepatitis C virus infection: The dermatological perspective

Acta Dermatovenerologica Alpina, Pannonica et Adriatica

Volumn 12, Issue 1, 2003, Pages 19-27

  Matičič, Mojca ^a  

^a UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

Author keywords

Hepatitis C; Lichen planus; Mixed cryoglobulinemia; Porphyria cutanea tarda; Sj gren's syndrome

Indexed keywords

ALPHA INTERFERON; MACROGOL; RIBAVIRIN;

ACNE; ALOPECIA; CHRONIC HEPATITIS; CLINICAL FEATURE; CRYOGLOBULINEMIA; DISEASE ASSOCIATION; DRY SKIN; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHEMA; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOBLOTTING; INJECTION SITE; LICHEN PLANUS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; LIVER TRANSPLANTATION; NAIL DISEASE; NONHUMAN; OUTCOMES RESEARCH; POLYMERASE CHAIN REACTION; PORPHYRIA CUTANEA TARDA; POSTTRANSFUSION HEPATITIS; REVIEW; SCREENING TEST; SJOEGREN SYNDROME; SKIN MANIFESTATION; VIRUS TRANSMISSION;

EID: 0037353691     PISSN: 13184458     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (61)

1. Choo Q-L, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989, 244: 359-62.
2. World Health Organisation. Hepatitis C - global prevalence (update). Wkly Epidemiol Rec 2000; 75: 18-9.
3. Armstrong GL, Alter MJ, McQuillian GM, Margolis HS. The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. Hepatology 2000; 31: 777-82.
4. Anonymous. EASL international consensus conference on hepatitis C in Paris 1999. Consensus statement. J Hepatol 1999; 30: 956-61.
5. Davis GL, Albright JE, Cook S, et al. Projecting the future healthcare burden from hepatitis C in the United States (Abstract). Hepatology 1998; 28: 390.
6. Neumann AU, Lam NP, Dahari H., et al. Hepatitis C viral dinamics in vivo and the antiviral efficacy of interferon alpha therapy. Science 1998; 282: 103-7.
7. Mondelli MU. Is there a role for immune responses in the pathogenesis of hepatitis C? J Hepatology 1996; 25: 232-8.
8. Cerny A, Chisari FV. Pathogenesis of chronic hepatitis C: immunological features of hepatic injury and viral persistence. Hepatology 1999; 30: 595-601.
9. Pawlotsky JM, Yahia MB, Andre C, et al. Immunological disorders in C virus chronic active hepatitis: a prospective case-control study. Hepatology 1994; 19: 841-8.
10. Clifford BD, Donahue D, Smith L, et al. High prevalence of serological markers of autoimmunity in patients with chronic hepatitis C. Hepatology 1995; 21: 613-9.
11. Alter MJ. The detection, transmission and outcome of hepatitis C virus infection. Infect Agents Dis 1993; 2: 155-66.
12. Abildgaard N, Petershund N. Hepatitis C transmitted by tattooing needle. Lancet 1991; 38: 288-91.
13. Seme K, Poljak M, Žužek-Rešek S, Avšič-Županc T. High prevalence of hepatitis C virus infection in hemodialysis patients from one dialysis unit in Slovenia. Nephron 1995; 71: 99-100.
14. Howard RJ, Fry DE, Davis JM, Wiley TE, Rice CL. Hepatitis C virus infection in healthcare workers. J Am Coll Surg 1997; 184: 540-52.
15. Utsumi T, Hashimoto E, Okumura Y, et al. Heterosexual activity as a risk factor for the transmission of hepatitis C virus. J Med Virol 1995; 46: 122-5.
16. Tor J, Libre JM, Carbonell M, et al. Sexual transmission of hepatitis C virus and its relation with hepatitis B virus and HIV. BMJ 1990; 301: 1130-3.
17. Kudesia B, Ball G, Irving WL. Vertical transmission of hepatitis C. Lancet 1995; 345: 1122.
18. Nakashinm K, Ikematsu H, Hayashi J, Kishihara Y, Mitsutake A, Kashiwagi S. Intrafamilial transmission of hepatitis C virus among the population of an endemic area of Japan. JAMA 1995; 274: 1459-61.
19. Hoofnagle JH. Hepatitis C: the clinical spectrum of disease. Hepatology 1997; 26 (Suppl 1): 15S-20S.
20. Gumber SC. Hepatitis C: a multifaceted disease. Review of extrahepatic manifestations. Ann Intern Med 1995; 123: 615-20.
21. Zeuzem S, Feinman SV, Rasenack J, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2001; 343: 1666-72.
22. Lindsay KL, Trepo C, Heintges T, et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001; 34: 395-403.
23. Manns MP, McHutchinson JG, Gordon S, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358: 958-64.
24. Fried MW, Shiffman ML, Reddy RK, et al. Pegylated interferon alfa-2a in combination with ribavirin: efficacy and safety results from a phase HI, randomized, actively controlled, multicenter study. Gastroenterology 2001; 120: A55.
25. Bonkovsky HL, Mehta S. Hepatitis C: A review. J Amer Acad Dermatol 2001; 44: 159-79.
26. Jackson JM. Hepatitis C and the skin. Dermatol Clin 2002; 20: 237-51.
27. Levey JM, Bjornsson B, Kuhns M, et al. Mixed cryoglibulinemia in chronic hepatitis C infection: a clinico-pathologic analysis of 10 cases and review of recent literature. Medicine 1994; 73: 53-67.
28. Pascual M, Perrin L, Giostra E, Shifferli JA. HCV in patients with cryoglobulinemia type II. J Infect Dis 1990; 162: 569-70.
29. Pechere-Bertchi A, Perrin L, De Saussure P, Widmann JJ, Giostra E. Hepatitis C: a possible etiology for cryoglobulinemia type II. Clin Exp Immunol 1992; 89: 419-22.
30. Lunel F, Musset L, cacoud P, et al. Cryoglobulinemia in chronic liver diseases: role of hepatitis C virus and liver damage. Gastroenterology 1994; 106: 1291-1300.
31. Agnello V, Chung RT, Kaplan LM. A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med 1992; 327: 1490-5.
32. Sansonno D, Cornacchiulo V, Iacibelli AR, Di Stefano RD, Lospalluti M, Dammacco F. Localization of hepatitis C virus antigens in liver and skin tissues of chronic hepatitis C virus-infected patients with mixed cryoglobulinemia. Hepatology 1995; 21: 305-12.
33. Bonkovsky HL, Poh-Fitzpatrick M, pimstone N, et al. Porphyria cutanea tarda, hepatitis C, and HFE gene mutations in North America. Hepatology 1998; 27: 1661-9.
34. Jackson JM, Callen JP. Scaring alopecia and sclerodermatous changes of the scalp in a patient with hepatitis C infection. J Am Acad Dermtol 1998; 39: 824-6.
35. D'Alessandro-Gandolfo L, Biocaiti G, Griso D, Marci A, Topi G. Frequency of viral hepatitis markers in porphyria cutanea tarda. Eur J Dermatol 1993; 3: 180-2.
36. Navas S, Bosch O, Castillo I, Marriott E, Carreno V. Porphyria cutanea tarda and hepatitis C and B virus infection: a retrospective study. Hepatology 1995; 21: 279-84.
37. Kondo M, Horie Y, Okano JI, et al. High prevalence of hepatitis C virus infection in Japanese patients with porphyria cutanea tarda (Letter). Hepatology 1997; 26: 246.
38. Stölzel U, Kostler E, Koska C, et al. Low prevalence of hepatitis C virus infection in porphyria cutanea tarda in Germany. Hepatology 1995; 21: 1500-3.
39. Malina L, Stransky J, Zdarsky E. Geographical differences in prevalence of hepatitis C virus infection in PCT (porphyria cutanea tarda). Br J Dermatol 1997; 136: 287-8.
40. Mokni M, Rybojad M, Puppin D, at al. Lichen planus and hepatitis C virus. J Am Acad Dermatol 1991; 24: 792.
41. Bagan JV, Ramon C, Gonzalez L, et al. Preliminary investigation of the association of oral lichen planus and hepatitis C. Oral Surg Oral Med Oral Pathol 1998; 85: 532-6.
42. Lodi G, Porter SR. Hepatitis C virus infection and lichen planus: a short review. Oral Dis 1997; 3: 77-81.
43. Cribier B, Garnier C, Laustriat D, Heid E. Lichen planus and hepatitis C virus infection: an epidemiologic study. J Am Acad Dermatol 1994; 31: 1070-2.
44. Nagao Y, Sata M, Tanikawa K, Itoh K, Kameyama T. Lichen planus and hepatitis C virus in the northern Kyushu region of Japan. Eur J Clin Inv 1995; 25: 910-4.
45. Grote M, Reichart PA, Berg T, Hops U. Hepatitis C virus (HCV)-infection and oral lichen planus. J Hepatol 1998; 29: 1034-5.
46. Mignogna M, Fedele S, Lo Russo L, Ruoppo E, Adamo D, Lo Muzio L. Extrahepatic manifestations of hepatitis c virus infection: the slowly unraveling picture of oral lichen planus (Letter). J Hepatol 2002; 37: 412-3.
47. Mignogna MD, Muzio LL, Favia G, Mignogna RE, Carbone R, Bucci E. Oral lichen planus and HCV infection: a clinical evaluation of 263 cases. Int J Dermatol 1998; 37: 575-8.
48. Matičič M, Poljak M, Kramar B, Seme K, Brinovec V, Meglič-Volkar J, et al. Detection of hepatitis C virus RNA from gingival crevicular fluid and its relation to virus presence in saliva. J Periodontol 2001; 72: 11-16.
49. Erkek E, Bozdogan Ö, Olut AI. Hepatitis C virus infection prevalence in lichen planus: examination of lesional and normal skin of hepatitis C virus-infected patients with lichen planus for the presence of hepatitis C virus RNA. Clin Exper Dermatol 2001; 26: 540-4.
50. Arrieta JJ, Rodriguez-Inigo E, Casqueiro M, et al. Detection of hepatitis C virus replication by in situ hybridisation in epithelial cells of anti-hepatitis C virus-positive patients with and without oral lichen planus. Hepatol 2000; 32: 97-103.
51. Eversole LR. Immunopathology of oral mucosal ulcerative, desquamative, and bullous diseases. Selective review of the literature. Oral Surg Oral Med Oral pathol 1994; 77: 555-71.
52. Divano MC, Prodi A, Rebora A. Anti-GOR antibodies in lichen planus. Dermatology. 1994; 188: 205-206.
53. Ramos-Casals M, Garcia-Carrasco M, Cervera R, Font J. Sjögren's syndrome and hepatitis C virus. Clin Rheumatol 1999; 18: 93-100.
54. Arrieta JJ, Rodriguez-Inigo E, Ortiz-Movilla N, et al. In situ detection of hepatitis C virus RNA in salivary glands. Am J Pathol 2001; 158: 259-264.
55. Tomšič M, Logar D, Grmek M, Perkovič T, Kveder T. Prevalence of Sjögren's syndrome in Slovenia. Rheumatol 1999; 38: 164-170.
56. Smith R, Caul EO, Burton JL. Urticaria and hepatitis C (Letter). Br J Dermatol 1997; 136: 980.
57. Doutre MS, Beylot-Barry M, Beylot C. Urticaria and hepatitis C infection. Br J Dermatol 1998; 138: 194-5.
58. Kanazawa K, Yaoita H, Tsuda F, Murata K, Okamoto H. Association of prurigo with hepatitis C virus infection. Arch Dermatol 1995; 131: 852-3.
59. Carson CW, Conn D, Czaja AJ, Wright TL, Brecher ME. Frequency and significance of antibodies to hepatitis C virus in polyarteritis nodosa. J Rheumatol 1993; 20: 304-9.
60. Taglione E, Vatteroni ML, Martin P, et al. Hepatitis C virus infection: prevalence in psoriasis and psoriatic arthritis. J Rheumatol 1999; 26: 370-2.
61. Doutre MS. Hepatitis C virus-related skin diseases. Arch Dermatol 1999; 135: 1401-3.